YM BIOSCIENCES REPORTS THIRD QUARTER 2009 OPERATIONAL AND FINANCI...(equipment 19806 20781 ...)

Date:5/14/2009

equipment 19,806 20,781 57,282 106,364 Amortiza- tion of intangible assets 265,135 265,135 795,406 795,406 Loss on disposal of property and equipment - - - 70,143 Unrealized loss (gain) on short-term deposits 56,219 (98,443) 33,501 (91,569) Stock-based compensation 195,023 324,704 574,579 1,827,991 Change in non-cash operating working capital: Accounts receivable and prepaid expenses 255,258 257,614 (45,639) (152,916) Accounts payable, accrued liabili- ties and deferred revenue (767,508) (849,632) (3,036,153) (4,204,800) ------------------------------------------------------------------------- (3,450,906) (3,898,488) (11,426,460) (13,572,225) Investing activities: Short-term deposits, net 4,233,479 (4,980,923) 17,259,293 10,362,066 Additions to property and equipment and intangible assets (19,114) - (34,150) (35,933) Proceeds from sale of property and equipment - - - 38,996 ------------------------------------------------------------------------- 4,214,365 (4,980,923) 17,225,143 10,365,129 ------------------------------------------------------------------------- Increase (decrease) in cash and cash equivalents 763,459
'/>"/>

SOURCE YM BioSciences Inc. Copyright©2009 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11
Related biology technology :

1. Frost & Sullivan Awards Precision Biosciences for Technology Innovation and Molecular Design Process in the Genomics Market
2. Neurocrine Biosciences to Present at the Deutsche Bank 34th Annual Health Care Conference
3. MichBio Leader Cites New Senate Biosciences Task Force and House Subcommittee as Evidence of States Growing Awareness of Industrys Economic Importance
4. Neurocrine Biosciences Reports First Quarter 2009 Results
5. Sangamo BioSciences Receives $100,000 Grand Challenges Explorations Grant for Innovative Global Health Research
6. Sangamo BioSciences Announces Publication in Nature of the Use of Zinc Finger Nucleases to Accelerate Precision Trait Stacking in Commercial Crop Species
7. ImQuest BioSciences and Arisyn Therapeutics Announce Strategic Partnership to Develop Infectious Disease and Cancer Drugs
8. LaVoie Group Selected by Vaccine Developer, Profectus BioSciences, as Agency of Record
9. Former GE Healthcare Director, Per Foss Appointed CEO for HUNT Biosciences
10. Sangamo BioSciences Announces First Quarter 2009 Conference Call and Webcast
11. Cell Biosciences Launches Next-Generation Protein Characterization System